MediNect Ophtho

Our new blog - The subretinal fibrosis model: The new norm for modelling wet AMD Great model for subretinal fibrosis AND VEGF non-responders. #preclinicalresearch #blog #ARVO #Subretinalfibrosis #retinaldisease #VEGFnonresponders

We are excited to welcome Mary Hanna to the MediNect team!    With over 12 years of experience in biomedical research within the higher education sector, Mary has brought exceptional knowledge and dedication to her role already in the time she has been with us. Her meticulous work and passion for advancing the field make her a great fit for our culture of excellence and innovation. We’re excited to continue to see the impact Mary will have at MediNect.    Welcome aboard!

MediNect Ophtho is proud to celebrate World Sight Day 2024 today, a reminder to prioritise our vision and ‘love our eyes’, with a special focus on children’s eye health worldwide. We’re privileged to play a part in the development of new therapies to combat vision loss and protect eyesight for future generations. We look forward to the World Sight Day meeting in Belfast each year, where we celebrate the remarkable progress being made locally and globally in vision health. If you're at the meeting, visit our Senior Study Director Dr Kevin Harkin at poster 34 to hear about our FFA grading strategy. Thank you to Dr Tunde Peto and her team for another excellent meeting, and we look forward to seeing you again tomorrow at the Pan-Ireland Ophthalmology Day meeting! #WorldSightDay #ChildrenLoveYourEyes #VisionForAll #EyeHealth #SightMatters #PreclinicalResearch #WSD2024

We’re thrilled to welcome Dr. Madeleine Smith to the MediNect team! Maddie recently completed her PhD in the Costa Lab at the Wellcome-Wolfson Institute for Experimental medicine in Queen's University Belfast, where her cutting-edge research explored how RNA-binding proteins regulate mRNA distribution and protein translation during blood vessel development. At MediNect Ophtho, Maddie will be using her expertise in angiogenesis and in vitro models to help develop innovative cell-based systems for studying retinal disease therapies. We’re excited to see her apply her research in this space, advancing our mission to transform retinal healthcare. Please join us in giving Maddie a warm welcome to the team! We’re excited to collaborate with her, and we know her contributions will make a huge impact in the biotech community.

Also happening now in Barcelona! While our CEO is across town, our Scientific Advisor, Dr Tine Van Bergen, and Business Development Manager, Hanagh Winter, are at the EURETINA Innovation Spotlight! They're looking forward to an excellent programme of talks and eager to explore ways we can collaborate to drive retinal research. If you're at the event, connect with them to discover how we can assist with your retinal innovations. We look forward to seeing you there! 📍CCIB, Barcelona #EURETINA2024 #RetinaTechnology #HealthcareInnovation #TeamEngagement #BarcelonaLive #RetinaAdvancements #InnovationInSight

Live from Barcelona! Our CEO, Dr James Bojdo, is at the Ophthalmology Futures Retina Forum today, ready to engage with innovators and leaders in retina care. If you're attending, don't miss the opportunity to connect and discuss opportunities for collaboration with MediNect Ophtho. 📍Esferic, Barcelona #OphthalmologyFutures #RetinaInnovation #HealthcareLeadership #CEOEngagement #EyeCareAdvancement #BarcelonaLive #InnovationInSight

We're looking forward to attending the EURETINA Conference in Barcelona next week! Our CEO, Dr. James Bojdo, and our scientific advisor, Dr. Tine Van Bergen, will be available for meetings throughout the event. If you’re attending and would like to explore potential collaborations or discuss industry insights, we’d love to set up a meeting. Please feel free to get in touch. #EURETINA2024 #Ophthalmology #Innovation #Networking #PreclinicalOphthalmology

Discover innovative models advancing #DryAMD research, including a cutting-edge laser-induced model we're excited to add to our repertoire. In our latest newsletter, we explore the preclinical models driving dry AMD and #GeographicAtrophy therapeutic strategies. 👉 Click the link to read the full newsletter and explore the options for innovators setting out to find the next treatments for dry AMD. #Ophthalmology #AMDResearch #RetinalResearch #PreclinicalResearch #TeamGrowth #InnovationInMedicine

We are thrilled to welcome Dr Sudha Priya Soundara Pandi to our team! Sudha brings over 15 years of expertise in cell and molecular biology, with a decade dedicated to ophthalmology research across academic and industrial settings. Sudha completed her Ph.D. at Queen's University Belfast, focusing on microRNA in aging and Age-related Macular Degeneration (AMD). Her technical expertise will add to the high quality of work we produce. Her diverse experience spans establishing CRISPR-Cas9 gene editing at King's College London, developing an innovative central sparing progressive retinal degeneration model at the University of Southampton, establishing an ex vivo vitreous stability model at Oxular Ltd, and leading preclinical gene therapy projects at Novartis, UK. She has also excelled in molecular diagnostics, leading a 12-member team at Primer Design, UK, and successfully launching multiple products. In addition to her research, Sudha has been a dedicated mentor, managing and training Ph.D. students, post-docs, scientists, research associates and technicians. Her proficiency in in vitro, in vivo, ex vivo, and human sample processing makes her an invaluable addition to our team. Stay tuned for more information on the exciting new #GeographicAtrophy model that Sudha brings, developed in Prof. Lotery's lab. Reach out to Sudha to learn more about her innovative work and how it could impact your projects. Plus, keep an eye out for more new team member announcements in the coming weeks! #TeamGrowth #GeographicAtrophy #Ophthalmology #PreclinicalModels #Innovation

We're pleased to share our latest blog post on preclinical models of dry Age-related Macular Degeneration (AMD). Click the link below to explore some of the options in preclinical modelling to understand and address this challenging condition. 🔗 https://lnkd.in/dBRh4gJt This month's blog covers: 💡Current preclinical models in dry AMD research. 💡How these models contribute to developing new treatments. Why it matters? AMD remains a leading cause of vision loss worldwide, predicted to affect more than 287 million people by 2040 with 8 out of every 10 developing dry AMD. Carefully planned and well considered preclinical work can propel your therapeutics forward and pave the way for effective therapies that can significantly improve patients' lives. Stay tuned for more dry AMD focused updates and insights in the coming weeks. #DryAMD #AMD #MacularDegeneration #Research #Ophthalmology #VisionHealth